Physician profile
Kevin Hess
NPI 1427004126
$27,508.71
in general payments reported to CMS, 2019-2025
10 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $101 · 2022: $1,100 · 2023: $22K · 2024: $4,228 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Travel and Lodging: $2,510 · Food and Beverage: $1,877 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,350.00 |
| Travel and Lodging | $2,510.31 |
| Food and Beverage | $1,877.26 |
| Education | $250.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24,891.75 | 2022-2024 | |
| Neuronetics, INC. | $1,088.96 | 2022-2023 | Neurostar Tms Therapy System |
| Neurocrine Biosciences, INC. | $282.30 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $271.49 | 2023-2024 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $263.91 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $240.57 | 2019-2024 | Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $174.35 | 2020-2024 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $143.49 | 2024-2025 | Fanapt |
| Astrazeneca Pharmaceuticals LP | $124.62 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2024 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.